86 related articles for article (PubMed ID: 14575579)
1. [Anemia in patients on combined androgen block therapy for prostate cancer].
Hua LX; Wu HF; Sui YG; Cheng SG; Xu ZQ; Zhang W
Zhonghua Zhong Liu Za Zhi; 2003 Sep; 25(5):496-7. PubMed ID: 14575579
[TBL] [Abstract][Full Text] [Related]
2. Anemia in patients on combined androgen block therapy for prostate cancer.
Qian LX; Hua LX; Wu HF; Sui YG; Cheng SG; Zhang W; Li J; Wang XR
Asian J Androl; 2004 Dec; 6(4):383-4. PubMed ID: 15546035
[TBL] [Abstract][Full Text] [Related]
3. Combined androgen blockade-induced anemia in prostate cancer patients without bone involvement.
Bogdanos J; Karamanolakis D; Milathianakis C; Repousis P; Tsintavis A; Koutsilieris M
Anticancer Res; 2003; 23(2C):1757-62. PubMed ID: 12820454
[TBL] [Abstract][Full Text] [Related]
4. How are hemoglobin levels affected by androgen deprivation in non-metastatic prostate cancer patients?
Choo R; Chander S; Danjoux C; Morton G; Pearce A; Deboer G; Szumacher E; Loblaw A; Cheung P; Woo T
Can J Urol; 2005 Feb; 12(1):2547-52. PubMed ID: 15777493
[TBL] [Abstract][Full Text] [Related]
5. Anaemia following initiation of androgen deprivation therapy for metastatic prostate cancer: a retrospective chart review.
Curtis KK; Adam TJ; Chen SC; Pruthi RK; Gornet MK
Aging Male; 2008 Dec; 11(4):157-61. PubMed ID: 18937151
[TBL] [Abstract][Full Text] [Related]
6. Effect of androgen suppression on hemoglobin in prostate cancer patients undergoing salvage radiotherapy plus 2-year buserelin acetate for rising PSA after surgery.
Chander S; Choo R; Danjoux C; Morton G; Pearse A; Deboer G; Szumacher E; Loblaw A; Cheung P; Woo T
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):719-24. PubMed ID: 15936551
[TBL] [Abstract][Full Text] [Related]
7. Transfusion-dependent anemia after initiation of androgen deprivation therapy for metastatic prostate cancer.
Curtis KK; Pruthi RK; Fonseca R; Gornet MK
Urology; 2007 Oct; 70(4):811.e5-8. PubMed ID: 17991572
[TBL] [Abstract][Full Text] [Related]
8. The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer: A multivariate analysis of Southwest Oncology Group Study 8894.
Beer TM; Tangen CM; Bland LB; Hussain M; Goldman BH; DeLoughery TG; Crawford ED;
Cancer; 2006 Aug; 107(3):489-96. PubMed ID: 16804926
[TBL] [Abstract][Full Text] [Related]
9. [High-dose induction therapy followed by maintenance with recombinant human erythropoietin for 30 patients with tumor-related anemia].
Xu F; Zhang L; Xiang XJ; Wang ZQ; Zhou ZM; Wang SY
Ai Zheng; 2006 Sep; 25(9):1120-2. PubMed ID: 16965653
[TBL] [Abstract][Full Text] [Related]
10. [Improvement of anemia and quality of life of patients with prostate cancer by treatment with human recombinant erythropoietin].
Queipo Zaragozá JA; Chicote Pérez F; Beltrán Meseguer JF; Borrell Palanca A; Giner Marco V; Esteve Claramunt J; Pastor Sempere F
Arch Esp Urol; 2004; 57(1):35-40. PubMed ID: 15112869
[TBL] [Abstract][Full Text] [Related]
11. Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study.
Aapro M; Leonard RC; Barnadas A; Marangolo M; Untch M; Malamos N; Mayordomo J; Reichert D; Pedrini JL; Ukarma L; Scherhag A; Burger HU
J Clin Oncol; 2008 Feb; 26(4):592-8. PubMed ID: 18235117
[TBL] [Abstract][Full Text] [Related]
12. The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score.
Nishiyama T; Ikarashi T; Hashimoto Y; Wako K; Takahashi K
J Urol; 2007 Oct; 178(4 Pt 1):1282-8; discussion 1288-9. PubMed ID: 17698092
[TBL] [Abstract][Full Text] [Related]
13. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
[TBL] [Abstract][Full Text] [Related]
14. Hemoglobin levels do not predict biochemical outcome for localized prostate cancer treated with neoadjuvant androgen-suppression therapy and external-beam radiotherapy.
Pai HH; Ludgate C; Pickles T; Paltiel C; Agranovich A; Berthelet E; Duncan G; Kim-Sing C; Kwan W; Lim J; Liu M; Tyldesley S
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):990-8. PubMed ID: 16682135
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
Miyake H; Hara I; Eto H
BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202
[TBL] [Abstract][Full Text] [Related]
16. Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy.
Bruchovsky N; Klotz L; Crook J; Goldenberg SL
Cancer; 2007 Mar; 109(5):858-67. PubMed ID: 17265527
[TBL] [Abstract][Full Text] [Related]
17. Influence of hot flashes on quality of life in patients with prostate cancer treated with androgen deprivation therapy.
Nishiyama T; Kanazawa S; Watanabe R; Terunuma M; Takahashi K
Int J Urol; 2004 Sep; 11(9):735-41. PubMed ID: 15379937
[TBL] [Abstract][Full Text] [Related]
18. [Anemia and neoadjuvant hormone therapy in radical surgery of localized cancer of the prostate].
Arango Toro O; Lorente Garín JA; Bielsa Gali O; Griño Garreta J; Gelabert Mas A
Actas Urol Esp; 2001 Feb; 25(2):105-9. PubMed ID: 11345792
[TBL] [Abstract][Full Text] [Related]
19. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
Voravud N; Sriuranpong V
J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
[TBL] [Abstract][Full Text] [Related]
20. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
